News & Updates

Another feather may have been added in the cap of glucagon-like protein-1 receptor agonists (GLP-1 RAs) – the class of type 2 diabetes (T2D) drugs that has become a blockbuster recently due to their remarkable weight loss benefit – as evidence of their potential to reduce the risk of obesity-associated cancers (OACs) comes to light.

Higher consumption of raw cruciferous vegetables appears to reduce the risk of recurrence in nonmuscle-invasive bladder cancer (NMIBC) patients treated with induction bacillus Calmette-Guérin (BCG), suggests a study.

In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the use of enzalutamide yields small improvements in outcomes when compared with abiraterone acetate, according to a retrospective study.

For small-sized melanoma in situ (MIS; <10 mm) on low-risk body sites, wide local excision (WLE) using a 5-mm margin was associated with a low rate of recurrence, a retrospective case series study has shown.

In older patients with untreated mantle cell lymphoma (MCL), the addition of the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to bendamustine and rituximab (ABR) conferred a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a favourable trend for overall survival (OS), findings from the phase III ECHO trial have shown.

A strong, positive link between BMI and the risk of colorectal cancer (CRC) incidence and related deaths has been found in Asian populations.